People who live past 110 — supercentenarians — appear to share a distinctive immune feature: an abundance of a rare, dual-purpose T cell that may help keep them healthy.
Researchers at Osaka University, led by Kosuke Hashimoto, studied immune cells from 28 adults across three age bands — 70–99, 100–109, and 110+ — publishing in Cell Reports.
What these cells are
CD4 cytotoxic T lymphocytes (CD4 CTLs) are hybrid cells combining features of helper and killer T cells.
The standard division of labour is clear: CD4 helper T cells coordinate immune responses by signalling to other cells, while CD8 cytotoxic T cells do the killing. CD4 CTLs break that rule, carrying the CD4 marker of helper cells while possessing the machinery to kill directly.
They are uncommon in younger people and have historically been treated as a curiosity rather than a functionally important population.
The gradient
These cells rose sharply with age: about 4% of T cells in the 70–99 group, 9.6% in centenarians, and 17.6% in supercentenarians — nearly one-fifth of all circulating T cells.
The stepwise pattern across three bands is what makes this more than a curiosity. A single comparison between old and very old could reflect anything; a consistent gradient tracking with age suggests a process continuing rather than a one-off difference.
Why this cuts against the standard picture
Immune ageing is conventionally a story of decline. The thymus, which produces new T cells, atrophies from adolescence onward, so older adults rely increasingly on a shrinking pool of existing cells. The repertoire narrows, responses to new pathogens weaken, and vaccines work less well — a syndrome termed immunosenescence.
A T-cell population expanding substantially into extreme old age does not fit that narrative. “The selective expansion of certain T cells suggests that, even in extreme old age, the immune system may continue to adapt to age-related challenges,” Hashimoto said.
The proposed explanation
The researchers theorise these cells may provide early immune responses against cancer — catching threats before tumours become clinically detectable — potentially contributing to longevity.
The hypothesis has a logic. Cancer incidence rises steeply with age, and someone reaching 110 has avoided or survived a great deal of it. Immune surveillance against emerging malignancy is a plausible mechanism, and a cell type combining helper coordination with direct killing could in principle be effective at it.
The causality problem
Three interpretations fit the data equally well, and the study cannot separate them.
The protective reading is the appealing one: these cells help people survive to extreme age, and their abundance is part of why.
The consequence reading is at least as plausible: living 110 years means enormous cumulative exposure to pathogens, particularly persistent viruses such as cytomegalovirus that are known to drive expansion of similar T-cell populations. The cells may accumulate because of long life rather than causing it.
The survivorship reading is the most deflating: supercentenarians differ from the general population in countless ways, most of which are consequences of having survived rather than reasons for it, and any measurement taken in them will show differences.
The sample
28 adults across three bands is a very small study, and the supercentenarian group is necessarily smaller still.
That is unavoidable rather than sloppy. People over 110 are extraordinarily rare — a few hundred verified worldwide at any time — and recruiting them for immune profiling means finding individuals who are extremely old, willing, able to consent and reachable. Any study of this population is small by construction, which is why findings should be treated as hypothesis-generating.
What would test it
The useful next steps are clear. Measuring CD4 CTL levels in a large cohort of older adults and following them prospectively would establish whether abundance predicts survival, or merely accompanies it.
Characterising what these cells actually recognise would address the cancer hypothesis directly — if they target tumour-associated antigens, the theory strengthens considerably; if they are dominated by responses to persistent viruses, the consequence reading gains.
The problem with studying extreme longevity
Research on supercentenarians carries a structural difficulty that applies well beyond this finding.
These individuals are selected by survival, and survival to 110 requires avoiding every common cause of death for over a century. Any characteristic measured in them will differ from the general population, because the general population includes everyone who did not make it.
Distinguishing causes of longevity from consequences of it, and from coincidences, is therefore extremely hard. The gold standard would be measuring a characteristic in a large middle-aged cohort and following them for decades to see who survives — which for supercentenarian research means a study running eighty years.
The field compensates with family studies, since exceptional longevity clusters in families in ways suggesting genuine heritable contributions, and with animal work where lifespans permit experiment. Neither substitutes fully for the prospective human study nobody can run, which is why findings in this area remain suggestive for far longer than findings elsewhere.
Immune ageing is usually a story of decline, so signs of continued adaptation are intriguing. But this shows an association between these T cells and extreme longevity, not that boosting them would extend life. Research news, not medical advice.